We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Canada Clarifies Regulatory Pathway for Low Molecular Weight Heparins
Canada Clarifies Regulatory Pathway for Low Molecular Weight Heparins
October 8, 2013
Health Canada is asking generic drugmakers seeking approval of drugs containing low molecular weight heparins to use the approval pathway for subsequent entry biologics (SEB).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor